Prognostic value of baseline alkaline phosphatase of 177Lu‐PSMA radioligand therapy in metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis
Authors:
Open Access
- 12 December 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0307826
Abstract
Background: Current studies have shown inconsistent results regarding the impact of baseline alkaline phosphatase (ALP) levels on the prognosis of metastatic castration-resistant prostate cancer (mCRPC) patients who undergo 177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT). Therefore, a comprehensive meta-analysis is needed to clarify the implications. Methods: This study was carried out in full compliance with the PRISMA protocol 2020, and a comprehensive search was conducted through PubMed, Web of Science, and Embase for published literature up to April 1st, 2024. Random-effects models were used to assess the correlation between baseline ALP and overall survival (OS) or progression-free survival (PFS) of mCRPC patients treated with 177Lu-PRLT, with a significance level set at α = 0.05. Results: A total of 12 articles were included in this study. The pooled effect estimates for baseline ALP and OS were 1.134 (95% CI: 1.035–1.245), I2 = 78.7%, P < 0.05. Regarding baseline ALP and PFS, the pooled effect estimate was found to be 2.14 (95% CI: 1.232–3.718), I2 = 93.3%, P < 0.05. Subgroup analysis revealed minimal heterogeneity among articles using a cut-off value ≥220U/L when examining the association between baseline ALP and OS; whereas for baseline ALP and PFS, there was also minimal heterogeneity observed among articles that adjusted for confounders. Conclusion: This meta-analysis demonstrates a significant association between elevated baseline ALP levels in mCRPC patients prior to 177Lu-PRLT treatment and inferior OS and PFS. Timely monitoring of baseline ALP levels can provide valuable insights for clinical decision-making and patient counseling.Keywords
This publication has 53 references indexed in Scilit:
- 177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysisThe Prostate, 2022
- 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)European Journal of Nuclear Medicine and Molecular Imaging, 2021
- Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617European Journal of Nuclear Medicine and Molecular Imaging, 2020
- Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysisInternational Journal of Clinical Oncology, 2019
- PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survivalEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapyJournal of Medical Radiation Sciences, 2017
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- What's the Relative Risk?JAMA, 1998